Disease Treatment Sample Clauses

Disease Treatment. Treating gonorrhea during the pre-antibiotic era was unpleasant for the afflicted patient and rudimentary for the healthcare provider: physicians administered urethral irrigations with potassium permanganate and silver nitrate, while dysuria was treated with a soap and water enema and oral laudanum containing opium, which served to ease pain and discomfort. Patients were also advised to abstain from alcohol use and sexual contact during the treatment process (150). The modern era of antibiotic use to treat gonorrhea began in 1935 when Xxxxxxx Xxxxxx discovered the antibiotic sulphanilamide (1). In the late 1940’s, after 14 years of sulphanilamide use to treat gonorrhea, almost all (90%) of gonococcal clinical isolates were resistant to sulphonamides (99). Fortunately, in 1944 penicillin was available and first used to treat only sulphonamide-resistant cases of gonorrhea, but the drug quickly became the standard course of treatment (202). Gonococcal resistance to penicillin also arose, and in 1985 worldwide use of penicillin to treat gonorrhea ended (153, 163). Other families of antibiotics, including tetracyclines, aminoglycosides, macrolides, and fluoroquinolones have all been used to treat gonorrhea in the recent past, but resistance to all of these antibiotics has arisen in the gonococcus. Unfortunately, in 2007, the gonococcus joined the list of other “super bugs” due to its resistance to fluoroquinolone treatment. As mentioned earlier, current treatment for gonorrhea includes the use of third generation cephalosporins (i.e. ceftriaxone and cefixime), yet treatment failure using these drugs has been reported in Japan (46, 89, 214). The potential loss of third generation cephalosporins as a viable option for the treatment of gonorrhea is a pressing public health concern; therefore, understanding the mechanisms by which the gonococcus develops resistance to antibiotics is useful in helping to combat this serious sexually transmitted disease. Resistance to antimicrobial agents encountered by the gonococcus can develop in one of several ways, including entry exclusion, drug modification, target modification, or drug efflux.
AutoNDA by SimpleDocs

Related to Disease Treatment

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.

  • Emergency Medical Treatment I grant the Releasees permission to authorize emergency medical treatment as they deem appropriate, and agree that such action by the Releasees shall be subject to the terms of this Agreement. I understand and agree that the Releasees assume no responsibility for any injury or damage that might result from such emergency medical treatment.

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Sale Treatment The Company has determined that the disposition of the Mortgage Loans pursuant to this Agreement will be afforded sale treatment for accounting and tax purposes;

  • National Treatment and Most-favoured-nation Treatment (1) Each Contracting Party shall accord to investments of investors of the other Contracting Party, treatment which shall not be less favourable than that accorded either to investments of its own or investments of investors of any third State. (2) In addition, each Contracting Party shall accord to investors of the other Contracting Party, including in respect of returns on their investments, treatment which shall not be less favourable than that accorded to investors of any third State. (3) The provisions of paragraphs (1) and (2) above shall not be construed so as to oblige one Contracting Party to extend to the investors of the other the benefit of any treatment, preference or privilege resulting from: (a) Any existing or future free trade area, customs unions, monetary union or similar international agreement or other forms of regional cooperation to which one of the Contracting Parties is or may become a party, or (b) Any matter pertaining wholly or mainly to taxation.

  • National Treatment In the sectors inscribed in its Schedule, and subject to any conditions and qualifications set out therein, each Party shall accord to services and service suppliers of the other Party treatment no less favourable than that it accords, in like circumstances, to its own services and service suppliers.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • Corporate Treatment The Board shall use its reasonable best efforts to take such actions as are necessary or appropriate to preserve the status of the Company as a partnership for U.S. federal (and applicable state and local) income tax purposes. If, however, the Board determines, in its sole discretion, for any reason (including the proposal, formally or informally, of legislation that could affect the Company’s status as a partnership for U.S. federal and/or applicable state and local income tax purposes) that it is not in the best interests of the Company to be characterized as a partnership, the Board may take whatever steps, if any, are needed to cause the Company to be or confirm that the Company will be treated as an association or as a publicly traded partnership taxable as a corporation for U.S. federal (and applicable state and local) income tax purposes, including by making an election to be taxed as a “C” corporation pursuant to the Code (a “Change in Tax Classification”), without any approval or vote of the Members required, and to make such filings, including without limitation, a Form 8832 with the Service, and to undertake such actions as required to effect such Change in Tax Classification. At the time and following any Change of Tax Classification, the Board shall have the right, without any approval or vote of the Members being required, to amend this Agreement as reasonably required to effect the Change in Tax Classification and to provide for the operations of the Company following such event. Notwithstanding anything in this Agreement to the contrary, in the event U.S. federal (and/or applicable state and local) income tax laws, rules or regulations are enacted, amended, modified or applied after the date hereof in such a manner as to require or necessitate that the Company no longer be treated as a partnership for U.S. federal (and/or applicable state and local) income tax purposes, then the first sentence of this Section 8.7 shall no longer apply.

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • Denial of Preferential Tariff Treatment Except as otherwise provided in this Chapter, the importing Party may deny a claim for preferential tariff treatment or recover unpaid duties, where the good does not meet the requirements under this Chapter or Chapter Three (Rules of Origin).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!